A pharmacologist checks the reaction of cytotoxic drugs inside the containment facility at Natco Research Centre in the southern Indian city of Hyderabad March 13, 2012. India's move to strip German drugmaker Bayer of its exclusive rights to a cancer drug has set a precedent that could extend to other treatments, including modern HIV/AIDS drugs, in a major blow to global pharmaceutical firms, experts say. On Monday, the Indian Patent Office effectively ended Bayer's monopoly for its Nexavar drug and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India. REUTERS/Krishnendu Halder (INDIA - Tags: HEALTH BUSINESS)